{"disease":{"id":"severe-systemic-lupus-erythematosus-sle","name":"severe systemic lupus erythematosus sle"},"drugs":{"marketed":[{"drug_id":"anifrolumab","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphnelo","generic_name":"ANIFROLUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":59,"revenue":"700","mechanism":"Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response."},{"drug_id":"anifrolumab-fnia","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SAPHNELO","generic_name":"ANIFROLUMAB-FNIA","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}